Nanobiotix's first immuno-oncology trial approved by U.S. FDA
Tuesday, December 26, 2017
Nanobiotix SA Announces that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) Application for NBTXR3, a first-in-class nanoparticle designed for direct injection into cancerous tumors, activated by stereotactic ablative radiotherapy (SABR) and administered in combination with an anti-PD1 antibody (nivolumab or pembrolizumab).
First Nanobiotix immuno-oncology trial will be conducted in the U.S.
